U.S. markets close in 2 hours 22 minutes

H.C. Wainwright Reiterates Buy Rating for Co-Diagnostics (NASDAQ:CODX) Following News of Expansion into Africa

New York, Oct. 31, 2019 (GLOBE NEWSWIRE) -- H.C. Wainwright has reiterated their “Buy” rating for Co-Diagnostics, Inc. (CODX), a biotech with a patented platform for the development of molecular diagnostic tests, following news that the company continues to execute on its international expansion ambitions with the sale of equipment and malaria test kits to one of the largest private molecular diagnostics labs in Ghana.

The analyst’s report also reiterated their $2 price target on the back of several facts, including an evidently large market for malaria diagnostics in the country of Ghana. Malaria takes a heavy toll on residents of the country, being named as the #1 reason for patients’ frequent visits to hospitals, and as recently as 2015 the disease was responsible for 19% of recorded deaths in the country.

In addition to test kits for malaria, the company’s announcement and the subsequent analyst update point out that demand exists for other infectious disease diagnostics such as HIV, tuberculosis, HPV, and syphilis, the tests for which Co-Diagnostics expects to provide to their customer in the future. Of note is the fact that the installation is the only private molecular diagnostics laboratory in Kumasi, a city with itself roughly 1.7 million people and the capital of Ashanti, the most populated region in Ghana with an additional 4.1 million people.

These figures add up to Co-Diagnostics being the reagent provider for the sole private molecular diagnostics lab with access to 5.8 million people and a substantial infectious disease diagnostics market, a laudable first publicized foray into the African continent. This current milestone is supplemented by other recent announcements concerning domestic growth in their mosquito testing vertical, all of which inform Wainwright’s expectation of seeing further revenue streams to drive top-line growth for this up-and-coming biotech.

Disclosure: Co-Diagnostics Inc is a client of BDA International.

About BDA International, Inc.:

BDA International is an independent global Investor Relations firm offering a wide range of IR-related analysis, research and advisory services. In particular, we provide and are compensated for service packages that include strategic action plans and investor/market perception studies to help entities improve communication with customers and investors, and to increase their visibility. BDA International has received no direct compensation related to this release but its principles hold shares of client companies in our personal portfolios, including CODX. BDA International accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information. Parties interested in learning more about the relationship between BDA and CODX may do so via the contact information at the bottom of this release.

Disclaimer

The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the BDA may at times hold a position in the company covered within the article. Co-Diagnostics is a client of BDA International. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. BDA is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.

Investor Relations Contact:
M. Dost                                                               
BDA International  
www.bda-ir.com

dost@bda-ir.com